Pantothenate Kinase (PanK): A Promising Drug Target and Biomarker

Target Name: Pantothenate Kinase

NCBI ID: P42181

Pantothenate Kinase

Other Name(s): PanK

Pantothenate Kinase (PanK): A Promising Drug Target and Biomarker

Introduction

Pantothenate Kinase (nonspecific subtype) (PanK) is an enzyme that plays a crucial role in various cellular processes. It is a key enzyme in the citric acid cycle, also known as the Krebs cycle or tricarboxylic acid (TCA) cycle, which is responsible for generating energy in the form of ATP from glucose. PanK is critical for the synthesis of crucial molecules, such as carbonyl-CoA, which is a key intermediary in the citric acid cycle.

PanK is a protein that consists of 21 kDa伪-subunits and 4 kDa尾-subunits. It has a molecular weight of 41 kDa and a pI of 5.5. PanK is highly conserved, with significant sequence identity between its various subunits. It is found in various cellular organelles, including the mitochondria, endoplasmic reticulum, and cytosol.

PanK functions as a catalytic enzyme that catalyzes the conversion of carbonyl-CoA to succinyl-CoA via a series of intermediate steps. This reaction is a critical step in the citric acid cycle and is critical for the production of ATP energy. PanK is known to have various functions, including the regulation of cellular energy metabolism, cell growth, and cell death.

As a drug target, PanK has been identified as a potential target for various therapeutic strategies. The high level of PanK expression in cancer cells makes it an attractive target for cancer treatments. of cytotoxic drugs. Therefore, PanK has become a potential drug target.

PanK can also be used as a biomarker for cancer diagnosis. Because PanK has different expression levels in various cancers, it can be used as a tumor-specific indicator. By detecting the expression level of PanK, tumors can be analyzed qualitatively and quantitatively, thereby improving the accuracy and sensitivity of diagnosis.

Inhibition of PanK can lead to cell metabolism disorders and affect processes such as cell cycle, apoptosis, and growth. Therefore, PanK has become a potential anti-tumor drug target. Many anti-tumor drugs, such as chemotherapy drugs and radiotherapy drugs, have the ability to inhibit PanK activity.

In order to better understand the function and mechanism of PanK, researchers conducted various experiments. They found that PanK plays an important role in tumor growth and cell cycle regulation. In addition, they also found that PanK plays an important role in apoptosis. These findings provide new ideas and methods for inhibiting PanK activity.

Conclusion

Pantothenate Kinase (nonspecific subtype) (PanK) is an enzyme that plays a crucial role in various cellular processes. Its high level of conservation and various functions make it an attractive target for drug development. The inhibition of PanK has been shown to be a promising strategy for cancer treatment. Additionally, PanK has also been identified as a potential biomarker for cancer diagnosis. Further research is needed to fully understand the function and mechanism of PanK, and to develop new therapeutic strategies for the treatment of cancer.

Protein Name: Pantothenate Kinase (nonspecified Subtype)

The "Pantothenate Kinase Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Pantothenate Kinase comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets